Hepatitis Monthly

Published by: Kowsar

Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C

Simona Onali 1 , Ivana Maida 2 , Cinzia Balestrieri 3 , Francesco Arcadu 4 , Enrico Urru 1 , Davide Porcu 1 , Giancarlo Serra 3 , Giacomo Flore 2 , Elena Dore 2 , Caterina Satta 4 , Pier Paolo Bitti 5 , Maria Grazia Sanna 5 , Loredana Serusi 5 , Michele Casale 1 , Maria Conti 3 , Martina Loi 1 , Francesco Figorilli 1 , Maria Cristina Pasetto 1 , Sergio Babudieri 2 and Luchino Chessa 1 , 3 , *
Authors Information
1 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
2 Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
3 Liver Unit, Department of Internal Medicine, University Hospital of Cagliari, Cagliari, Italy
4 Internal Medicine and Gastroenterology, San Francesco Hospital, ASL 3, Nuoro, Italy
5 Immunohematology and Transfusional Medicine, San Francesco Hospital, ASL 3, Nuoro, Italy
Article information
  • Hepatitis Monthly: January 2018, 18 (1); e61453
  • Published Online: January 20, 2018
  • Article Type: Research Article
  • Received: September 6, 2017
  • Revised: November 29, 2017
  • Accepted: December 25, 2017
  • DOI: 10.5812/hepatmon.61453

To Cite: Onali S, Maida I, Balestrieri C, Arcadu F, Urru E, et al. Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C, Hepat Mon. 2018 ; 18(1):e61453. doi: 10.5812/hepatmon.61453.

Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43(8):638-40. [PubMed: 2119395].
  • 2. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21. [PubMed: 12070002].
  • 3. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116(16):2875-83. doi: 10.1182/blood-2009-11-248724. [PubMed: 20551378].
  • 4. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008;93(8):1243-6. doi: 10.3324/haematol.12554. [PubMed: 18556410].
  • 5. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89(10):1179-86. [PubMed: 15477201].
  • 6. Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 2012;91(9):1451-8. doi: 10.1007/s00277-012-1465-7. [PubMed: 22526366].
  • 7. Casu S, Balestrieri C, Figorilli F, Onali S, Serra G, Chessa L, et al. P1155 safety and efficacy of PEG IFnA 2a and ribavirin for treatment of hepatitis C in sardinian adult patients with thalassemia major, a single centre real life experience. J Hepat. 2014;60(1):468. doi: 10.1016/s0168-8278(14)61315-5.
  • 8. Paschos P, Vlachaki E, Pasvanti C, Sinakos E, Kalpaka A, Klonizakis P, et al. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience. Acta Haematol. 2011;126(4):231-3. doi: 10.1159/000330516. [PubMed: 21934299].
  • 9. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha 2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93(8):1247-51. doi: 10.3324/haematol.12352. [PubMed: 18556414].
  • 10. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005;130(4):644-6. doi: 10.1111/j.1365-2141.2005.05645.x. [PubMed: 16098081].
  • 11. Kamal SM, Fouly AH, Mohamed MK, Hochnikos BW, Lamont FT, Gohary IS, et al. 585 Peginterferon alpha 2b therapy with and without ribavirin in patients with thalassemia, a randomized study. J Hepatol. 2006;44:217. doi: 10.1016/s0168-8278(06)80585-4.
  • 12. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236-44. doi: 10.1111/j.1365-2893.2009.01170.x. [PubMed: 19638104].
  • 13. European Association for the Study of the Liver. Electronic address EEE. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153-94. doi: 10.1016/j.jhep.2016.09.001. [PubMed: 27667367].
  • 14. Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, et al. Elbasvir, grazoprevir for patients with hepatitis c virus infection and inherited blood disorders: A phase III study. Hepatology. 2017;66(3):736-45. doi: 10.1002/hep.29139. [PubMed: 28256747].
  • 15. Biliotti E, Palazzo D, Serani M, Silvestri AM, Volpicelli L, Esvan R, et al. Interferon free antiviral treatment of chronic hepatitis C in patients affected by beta-thalassemia major. Ann Hematol. 2017;96(6):1043-5. doi: 10.1007/s00277-017-2986-x. [PubMed: 28378040].
  • 16. Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017;46(4):424-31. doi: 10.1111/apt.14197. [PubMed: 28660640].
  • 17. Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic direct acting antivirals in treatment of chronic hepatitis c infection in patients of thalassemia major. J Clin Exp Hepatol. 2017;7(3):172-8. doi: 10.1016/j.jceh.2017.08.002. [PubMed: 28970702].
  • 18. Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with beta thalassaemia major and advanced liver disease. Br J Haematol. 2017;178(1):130-6. doi: 10.1111/bjh.14640. [PubMed: 28439915].
  • 19. Di Marco V, Bronte F, Cabibi D, Calvaruso V, Alaimo G, Borsellino Z, et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography, (TE) lack of interference by iron deposition. Br J Haematol. 2010;148(3):476-9. doi: 10.1111/j.1365-2141.2009.07996.x. [PubMed: 19930183].
  • 20. Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, et al. Age at infection affects the long term outcome of transfusion associated chronic hepatitis C. Blood. 2002;99(12):4588-91. doi: 10.1182/blood-2001-12-0192. [PubMed: 12036892].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments